Trends in the treatment and survival for local and regional cutaneous melanoma in a US population-based study

Melanoma Research

Volumn 21, Issue 6, 2011, Pages 547-554

  Harlan, Linda C ^a   Lynch, Charles F ^c   Ballard Barbash, Rachel ^a   Zeruto, Christopher ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INFORMATION MANAGEMENT SERVICES INC   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

sentinel lymph node biopsy; surgery; survival; treatment; tumor depth

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CAUCASIAN; CLINICAL FEATURE; DRUG USE; EARLY DIAGNOSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOCAL CUTANEOUS MELANOMA; LYMPH NODE BIOPSY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MELANOMA; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; REGIONAL CUTANEOUS MELANOMA; RESIDENCY EDUCATION; SENTINEL LYMPH NODE BIOPSY; SEX DIFFERENCE; SKIN CANCER; TREATMENT RESPONSE; TREND STUDY; TUMOR VOLUME; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEDICAL ONCOLOGY; MELANOMA; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; POPULATION; SEER PROGRAM; SKIN NEOPLASMS; SURVIVAL RATE; TUMOR BURDEN; UNITED STATES; YOUNG ADULT;

EID: 80955142764     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32834b58e4     Document Type: Article

References (22)

1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R,Waldron W, et al., editors. SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975-2008/, based on November 2010 SEER data submission, posted to the SEER website, 2011.
2. American Cancer Society. Cancer facts & figures 2011. Atlanta: American Cancer Society; 2011.
3. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the eastern cooperative oncology group trial EST 1684. J Clin Oncol 1996; 14:7-17.
4. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000; 18:2444-2458.
5. Kirkwood JM, Ibrahim J, Lawson DH, Atkins MB, Agarwala SS, Collins K, et al. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the multicenter eastern cooperative oncology group phase ii trial E2696. J Clin Oncol 2001; 19:1430-1436.
6. Haigh PI, DiFronzo LA, McCready DR. Optimal excision margins for primary cutaneous melanoma: a systematic review and meta-analysis. Can J Surg 2003; 46:419-426.
7. Mocellin S, Pasquali S, Nitti D. The impact of surgery on survival of patients with cutaneous melanoma. Ann Surg 2011; 253:239-243.
8. Thomas JM, Newton-Bishop J, A'Hern R, Coombes G, Timmons M, Evans J, et al. Excision margins in high-risk malignant melanoma. NEJM 2004; 350:757-766.
9. Wong JH, Wanek L, Chang LJ, Goradia T, Morton DL. The importance of anatomic site in prognosis in patients with cutaneous melanoma. Arch Surg 1991;126:486-489.
10. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127:392-399.
11. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, et al. Sentinel-node biopsy or observation in melanoma. NEJM 2006; 355:S1207-S1317.
12. Carlson GW, Page AJ, Cohen C, Parker D, Yaar R, Li A, et al. Regional recurrence after negative sentinel lymph node biopsy for melanoma. Ann Surg 2008; 248:378-386.
13. Wong SL, Kattan MW, McMasters KM, Coit DG. A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than the American joint committee on cancer staging system. Ann Surg Oncol 2005; 12:282-288.
14. Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. Clin Oncol 2002; 20:1818-1825.
15. Kirkwood JM, Tarhini AA, Moschos SJ, Panelli MC. Adjuvant therapy with high-dose interferon a 2b in patients with high-risk stage IIB/III melanoma. Nat Clin Pract Oncol 2007; 5:2-3.
16. Bajetta E. Adjuvant use of interferon a2b is not justified in patients with stage IIb/III melanoma. Nat Clin Pract Oncol 2007; 5:4-5.
17. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. JNCI 2010; 102:493-501.
18. Pennie ML, Soon SL, Risser JB, Veledar E, Culler SD, Chen SC. Melanoma outcomes for Medicare patients: association of stage and survival with detection by a dermatologist versus a nondermatologist. Arch Dermatol 2007; 143:488-494.
19. Rachet B, Quinn MJ, Coleman MP. Survival from melanoma of the skin in England and Wales up to 2001. BJC 2008; 99:547-559.
20. Hohnheiser AM, Gefeller O, Gohl J, Schuler G, Hohenberger W, Merkel S. Malignant melanoma of the skin: long-term follow-up and time to first recurrence. World J Surg 2011; 35:580-589.
21. Reyes Ortiz CA, Freeman JL, Kuo YF, Goodwin JS. The influence of marital status on stage at diagnosis and survival of older persons with melanoma. J Gerontol A Biol Sci Med Sci 2007; 62:892-898.
22. Clausen SP, Brady MS. Surgical margins in patients with cutaneous melanoma: assessing the adequacy of excision. Melanoma Res 2005; 15:539-542.